Your session is about to expire
← Back to Search
Anti-inflammatory
Treatment Sequence 2 for Osteoarthritis
Phase 2
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Summary
PH-797804 is a potent inhibitor of inflammatory mediators that have a potential role in pain signalling following nerve injury and inflammation. Blocking such mediators may potentially have a therapeutic benefit by reducing pain.
Eligible Conditions
- Osteoarthritis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Trial Design
4Treatment groups
Experimental Treatment
Group I: Treatment Sequence 4Experimental Treatment2 Interventions
Group II: Treatment Sequence 3Experimental Treatment2 Interventions
Group III: Treatment Sequence 2Experimental Treatment2 Interventions
Group IV: Treatment Sequence 1Experimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Naproxen
FDA approved
PH-797804
Not yet FDA approved
PH-797804
Not yet FDA approved
Placebo
1995
Completed Phase 3
~2670
Find a Location
Who is running the clinical trial?
PfizerLead Sponsor
4,625 Previous Clinical Trials
14,284,022 Total Patients Enrolled
48 Trials studying Osteoarthritis
28,527 Patients Enrolled for Osteoarthritis
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,518 Previous Clinical Trials
11,458,598 Total Patients Enrolled
49 Trials studying Osteoarthritis
36,781 Patients Enrolled for Osteoarthritis
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger